SCHEMBL1857413

SCHEMBL1857413

C[C@@H](Cl)c1ccc(F)cn1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
APLNR P35414 2/20 0.50
HDAC6 Q9UBN7 1/20 0.38
JAK3 P52333 6/20 0.37
JAK2 O60674 5/20 0.37
KCNH2 Q12809 2/20 0.37
HRH1 P35367 1/20 0.37
FFAR2 O15552 1/20 0.36
NTRK1 P04629 4/20 0.34
AURKA O14965 2/20 0.34
NTRK3 Q16288 2/20 0.34
NTRK2 Q16620 2/20 0.34
LCK P06239 2/20 0.34
RET P07949 2/20 0.34
FLT3 P36888 2/20 0.34
FYN P06241 1/20 0.34
IGF1R P08069 1/20 0.34
FGFR1 P11362 1/20 0.34
FLT1 P17948 1/20 0.34
LTK P29376 1/20 0.34
KDR P35968 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2110025 1.00 APLNR (0.50) APLNRHDAC6JAK3JAK2KCNH2
SCHEMBL179299 0.84 APLNR (0.51) APLNRHDAC6JAK3JAK2KCNH2
SCHEMBL19773427 0.80 APLNR (0.49) APLNRHDAC6JAK3JAK2KCNH2
SCHEMBL20821151 0.80 APLNR (0.49) APLNRHDAC6JAK3JAK2KCNH2
SCHEMBL475519 0.80 APLNR (0.53) APLNRHDAC6JAK3JAK2KCNH2
SCHEMBL25203689 0.80 APLNR (0.57) APLNRHDAC6JAK3JAK2KCNH2
SCHEMBL347080 0.80 APLNR (0.53) APLNRHDAC6JAK3JAK2KCNH2
SCHEMBL20743678 0.80 APLNR (0.49) APLNRHDAC6JAK3JAK2KCNH2
SCHEMBL588810 0.80 APLNR (0.53) APLNRHDAC6JAK3JAK2KCNH2
SCHEMBL29858360 0.80 APLNR (0.57) APLNRHDAC6JAK3JAK2KCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8158785-B2 5,7-disubstituted[1.3]thiazolo [4,5-D] pyrimidin-2(3H)-amine derivatives and their use in therapy ASTRAZENECA AB (SE) 2012-04-17 US disclosed
US-8158785-B2 5,7-disubstituted[1.3]thiazolo [4,5-D] pyrimidin-2(3H)-amine derivatives and their use in therapy ASTRAZENECA AB (SE) 2012-04-17 US disclosed
US-8158785-B2 5,7-disubstituted[1.3]thiazolo [4,5-D] pyrimidin-2(3H)-amine derivatives and their use in therapy ASTRAZENECA AB (SE) 2012-04-17 US disclosed
EP-2069364-B1 NOVEL 5, 7-DISUBSTITUTED [1, 3]THIAZOLO [4, 5-D]PYRIMIDIN-2 (3H)-ONE DERIVATIVES AND THEIR USE IN THERAPY ASTRAZENECA AB (SE) 2011-12-14 EP disclosed
EP-2069364-B1 NOVEL 5, 7-DISUBSTITUTED [1, 3]THIAZOLO [4, 5-D]PYRIMIDIN-2 (3H)-ONE DERIVATIVES AND THEIR USE IN THERAPY ASTRAZENECA AB (SE) 2011-12-14 EP disclosed
US-7960395-B2 5,7-disubstituted thiazolo[4,5-d]pyrimidines for the selective inhibition of chemokine receptors ASTRAZENECA AB (SE) 2011-06-14 US disclosed
US-7960395-B2 5,7-disubstituted thiazolo[4,5-d]pyrimidines for the selective inhibition of chemokine receptors ASTRAZENECA AB (SE) 2011-06-14 US disclosed
US-7960395-B2 5,7-disubstituted thiazolo[4,5-d]pyrimidines for the selective inhibition of chemokine receptors ASTRAZENECA AB (SE) 2011-06-14 US disclosed
US-20110105537-A1 5,7-DISUBSTITUTED THIAZOLO[4,5-D]PYRIMIDINES FOR THE SELECTIVE INHIBITION OF CHEMOKINE RECEPTORS ASTRAZENECA AB (SE) 2011-05-05 US disclosed
US-20110105537-A1 5,7-DISUBSTITUTED THIAZOLO[4,5-D]PYRIMIDINES FOR THE SELECTIVE INHIBITION OF CHEMOKINE RECEPTORS ASTRAZENECA AB (SE) 2011-05-05 US disclosed
US-20100035899-A1 5,7-DISUBSTITUTED[1.3]THIAZOLO[4,5-d]PYRIMIDIN-2(3H)-AMINE DERIVATIVES AND THEIR USE IN THERAPY ASTRAZENECA AB (SE) 2010-02-11 US disclosed
US-20100035899-A1 5,7-DISUBSTITUTED[1.3]THIAZOLO[4,5-d]PYRIMIDIN-2(3H)-AMINE DERIVATIVES AND THEIR USE IN THERAPY ASTRAZENECA AB (SE) 2010-02-11 US disclosed
US-20100035899-A1 5,7-DISUBSTITUTED[1.3]THIAZOLO[4,5-d]PYRIMIDIN-2(3H)-AMINE DERIVATIVES AND THEIR USE IN THERAPY ASTRAZENECA AB (SE) 2010-02-11 US disclosed
US-20080318981-A1 Novel Compounds 480 ASTRAZENECA AB (SE) 2008-12-25 US disclosed
US-20080318981-A1 Novel Compounds 480 ASTRAZENECA AB (SE) 2008-12-25 US disclosed
US-20080318981-A1 Novel Compounds 480 ASTRAZENECA AB (SE) 2008-12-25 US disclosed
WO-2008039139-A1 NOVEL 5,7-DISUBSTITUTED [1, 3] THIAZOLO [4, 5] PYRIMIDIN-2 (3H)-AMINE DERIVATIVES AND THEIR USE IN THERAPY ASTRAZENECA AB (SE) 2008-04-03 WO disclosed
WO-2008039138-A1 NOVEL 5, 7-DISUBSTITUTED [1, 3 ] THIAZOLO [4, 5-D] PYRIMIDIN-2 (3H)-ONE DERIVATIVES AND THEIR USE IN THERAPY ASTRAZENECA AB (SE) 2008-04-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080318981-A1 Novel Compounds 480 CX3CR1, CCR2, CXCR3 APLNR 352/4885HDAC6 1038/4885JAK3 1482/4885
US-20100035899-A1 5,7-DISUBSTITUTED[1.3]THIAZOLO[4,5-d]PYRIMIDIN-2(3H)-AMINE DERIVATIVES AND THEIR USE IN THERAPY CX3CR1, CCR2, CXCR3 APLNR 357/4885HDAC6 1501/4885JAK3 689/4885
US-20110105537-A1 5,7-DISUBSTITUTED THIAZOLO[4,5-D]PYRIMIDINES FOR THE SELECTIVE INHIBITION OF CHEMOKINE RECEPTORS CX3CR1, CCR2, CXCR3 APLNR 410/4885HDAC6 1815/4885JAK3 1140/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.